论文部分内容阅读
目的对比观察三磷酸腺苷与维拉帕米治疗阵发性室上性心动过速患者的临床效果。方法将阵发性室上性心动过速患者80例随机分为观察组和对照组各40例。观察组予三磷酸腺苷治疗,对照组予维拉帕米治疗,对比2组转复成功率、室上性心动过速终止时间及不良反应发生情况。结果 2组转复成功率和不良反应发生率比较差异无统计学意义(P>0.05)。观察组室上性心动过速终止时间短于对照组(P<0.05)。结论三磷酸腺苷与维拉帕米治疗阵发性室上性心动过速患者的临床疗效均显著,且不良反应发生率较低,但三磷酸腺苷治疗的患者室上性心动过速终止时间明显缩短,值得推广应用。
Objective To compare the clinical effects of adenosine triphosphate and verapamil in patients with paroxysmal supraventricular tachycardia. Methods Eighty patients with paroxysmal supraventricular tachycardia were randomly divided into observation group (40 cases) and control group (40 cases). The observation group was treated with adenosine triphosphate, the control group was treated with verapamil, the success rate of the two groups was compared, the termination of supraventricular tachycardia and the incidence of adverse reactions. Results There was no significant difference in success rate and adverse reaction between the two groups (P> 0.05). The termination time of supraventricular tachycardia in observation group was shorter than that in control group (P <0.05). Conclusions The clinical efficacy of adenosine triphosphate and verapamil in the treatment of patients with paroxysmal supraventricular tachycardia are significant, and the incidence of adverse reactions is low, but the termination of supraventricular tachycardia in patients treated with adenosine triphosphate is significantly shortened, it is worth promoting application.